πŸ‡ΊπŸ‡ΈUnited States

Protocol Approval Delays Driving Trial Start-Up Time Drag

1 verified sources

Definition

Prolonged IRB/IACUC approval and site activation processes delay trial initiation by weeks to months, incurring daily operational costs without revenue generation. Average site activation takes 13-25 weeks, with interventions showing potential 45% reduction.[2]

Key Findings

  • Financial Impact: $55,716 per day Phase III trial delay; ~$390,000 per delayed week per site
  • Frequency: Recurring per trial start-up cycle
  • Root Cause: Complex administrative coordination involving contracts, feasibility, and ethics reviews

Why This Matters

This pain point represents a significant opportunity for B2B solutions targeting Biotechnology Research.

Affected Stakeholders

CRO Start-Up Managers, Site Principal Investigators, Sponsor Finance Teams

Deep Analysis (Premium)

Financial Impact

$10,000-$50,000 in grant milestone delay penalties; Potential loss of future grant funding if multiple delays occur; Staff time spent managing funder communications and compliance explanations β€’ $390,000 per delayed week β€’ $390,000 per delayed week Γ— 2-3 weeks = $780,000 to $1,170,000 per resubmit

Unlock to reveal

Current Workarounds

Email alerts to sponsors, manual risk log in Excel, verbal escalation β€’ Email chains, manual document tracking, in-person lab meetings β€’ Email chains, shared Google Docs for protocol tracking, manual status monitoring via IRB portal

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

Request Deep Analysis

πŸ‡ΊπŸ‡Έ Be first to access this market's intelligence